Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | CBS | P35520 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316019 | 0.84 | ACHE (0.36) | ACHELTA4HHSP90AB1CBSCA12 | |
| SCHEMBL13492226 | 0.84 | GPR84 (0.39) | ACHELTA4HHSP90AB1PTGS2CYP3A4 | |
| SCHEMBL4780801 | 0.84 | ERN1 (0.36) | ACHELTA4HHSP90AB1CBSCYP3A4 | |
| SCHEMBL13224583 | 0.84 | CA12 (0.50) | ACHEBACE1LTA4HHSP90AB1CBS | |
| SCHEMBL13224699 | 0.84 | ALDH1A1 (0.50) | ACHEHSP90AB1PTGS2CYP3A4LCK | |
| SCHEMBL4561692 | 0.79 | CALM1 (0.56) | BACE1HSP90AB1PTGS2CYP3A4TYR | |
| SCHEMBL23568677 | 0.78 | — | — | |
| SCHEMBL28157468 | 0.77 | CBS (0.50) | ACHEBACE1LTA4HHSP90AB1CBS | |
| SCHEMBL14051491 | 0.76 | CALM1 (0.42) | LTA4HPTGS2 | |
| SCHEMBL1514254 | 0.76 | XDH (0.52) | ACHEBACE1LTA4HCBSPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775103-B | Resveratrol and preparation method and application thereof | 湖南复瑞生物医药技术有限责任公司 | 2025-05-27 | — | — | CN | claimed |
| CN-119775103-A | Resveratrol and preparation method and application thereof | 湖南复瑞生物医药技术有限责任公司 | 2025-04-08 | — | — | CN | claimed |
| CN-113372595-B | Rare earth metal complexing polyvinyl alcohol film and preparation method thereof | 贵州省材料产业技术研究院 | 2022-02-08 | — | — | CN | claimed |
| CN-113372595-A | Rare earth metal complexing polyvinyl alcohol film and preparation method thereof | 贵州省材料产业技术研究院 | 2021-09-10 | — | — | CN | claimed |
| CN-120289277-A | Preparation method of resveratrol, resveratrol and application of resveratrol | 湖南复瑞生物医药技术有限责任公司 | 2025-07-11 | — | — | CN | disclosed |
| CN-119775103-B | Resveratrol and preparation method and application thereof | 湖南复瑞生物医药技术有限责任公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119775103-B | Resveratrol and preparation method and application thereof | 湖南复瑞生物医药技术有限责任公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119775103-A | Resveratrol and preparation method and application thereof | 湖南复瑞生物医药技术有限责任公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119775103-A | Resveratrol and preparation method and application thereof | 湖南复瑞生物医药技术有限责任公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024145623-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-117164770-B | High-dispersion water reducer with shrinkage reducing function and preparation method thereof | 长江三峡技术经济发展有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117164770-A | High-dispersion water reducer with shrinkage reducing function and preparation method thereof | 长江三峡技术经济发展有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-2958897-A2 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015016729-A1 | UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014130582-A2 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2458995-A1 | TRISUBSTITUTED BORON-CONTAINING MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | DUNN JAMES PATRICK | 2010-02-18 | — | — | US | disclosed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080249137-A1 | PPAR active compounds | PLEXXIKON INC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249137-A1 | PPAR active compounds | PPARG, PPARA, PPARD | ACHE 3733/4885BACE1 2236/4885LTA4H 1796/4885 |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | CCR5, CXCR4, CCR1 | ACHE 3655/4885BACE1 2077/4885LTA4H 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.